Physician profile
Patricia L Weng
NPI 1730301656
$8,306.55
in general payments reported to CMS, 2019-2025
10 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 81% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $24.12 · 2022: $1.10 · 2023: $6,378 · 2024: $141 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,353 · Travel and Lodging: $1,195 · Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,352.50 |
| Travel and Lodging | $1,194.61 |
| Food and Beverage | $584.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,976.79 | 2023-2025 | Prevymis |
| Glaxosmithkline, LLC. | $3,900.00 | 2023 | |
| Alexion Pharmaceuticals, INC. | $182.36 | 2019-2024 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $62.12 | 2025 | Empaveli |
| Novo Nordisk INC | $54.68 | 2024-2025 | Rivfloza |
| Alnylam Pharmaceuticals INC. | $54.57 | 2023-2024 | Oxlumo |
| Upsher-Smith Laboratories LLC | $28.59 | 2024 | |
| Genzyme Corporation | $24.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.22 | 2024 | |
| Travere Therapeutics, INC. | $1.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.